1) Van Es N, et al. Edoxaban for the treatment of venous thromboembolism in patients with cancer - rationale and design of the Hokusai-VTE-cancer study. Thromb Haemost. 2015;114(6):1268-76. 2) Raskob GE, Van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia DA, et al. LBA-6 A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai-VTE-Cancer Study. Abstract presented at the Annual Society of Hematology Annual Meeting, 2017. 3) Raskob GE, van Es N, Verhamme, P, Carrier M, Di Nisio M, Garcia DA, et al. Edoxaban for the treatment of cancer-associated thromboembolism. N Engl J Med. 2017. DOI: 10.1056/NEJMoa1711948. 4) Khalil J, et al. Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol. 2015;13:204. 5) Mandalà M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 (Suppl 6): vi85-vi92. 6) Kearon C, Aki EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, et al. Antithrombotic therapy fir VTE disease. CHEST guidelines and expert panel report. Chest. 2016;149(2):315-52. 7) Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol. 2015;11(3) :e442-e444. 8) Hisada Y, et al. Venous Thrombosis and Cancer: from Mouse Models to Clinical Trials. J Thromb and Haemost. 2015;13(8):1372-82. 9) ClinicalTrials.gov. Cancer Venous Thromboembolism (VTE). Available at: https://clinicaltrials.gov/ct2/show/NCT0.... [Last accessed: December 2017]. 10) Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE) - Blood Clot Forming in a Vein. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/ncbddd/dvt/facts.html.... [Last accessed: December 2017]. 11) Van Beek E, et al. Deep vein thrombosis and pulmonary embolism. New York: John Wiley & Sons, 2009. Print. 12) Cohen A, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost. 2007;98(4) :756-64. 13) The Coalition to Prevent VTE. Available at: http://www.coalitiontopreventvte.org/IND... . [Last accessed: December 2017]. 14) Braekkan, S. K. et al. Body height and risk of venous thromboembolism: The Troms Study. Am J Epidemiol. 2010;171:1109-15. 15) Zagaria, M. Venous Thrombosis: Pathogenesis and Potential for Embolism. US Pharm. 2009;34:22-24. 16) Ay C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377-82. 17) Khorana AA, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634. 18) Lee AYY, Levine N. Venous thromboembolism and cancer: Risks and outcomes. Circ. 2003;107:I17-I21.
EDX/17/0329 Date of preparation: December 2017
(Logo: http://mma.prnewswire.com/media/618561/D... )
Photo: http://mma.prnewswire.com/media/618561/D...
Video: https://www.multivu.com/players/uk/8236751-daily-oral-lixian...
CONTACT: Lydia Worms (Europe), Daiichi Sankyo Europe GmbH, EdoxabanCommunications & Product PR Europe, +49-89-7808751
